News

Mr. Smith has nearly 35 years of broad and global experience in the pharmaceutical industry and most recently served as president and CEO of Ino Therapeutics, a specialty

The company does not expect to record Biomateriali revenue for the balance of 2007. It is expected that this acquisition will be dilutive in 2008. The Biomateriali acquisition

Similar applications for a parallel European Phase III trial are planned to be submitted to European regulatory agencies. Diamyd Medical anticipates that two successful Phase III studies, each

The filing is based on data from the 682 patient Phase III VISTA (Velcade as initial standard therapy in multiple myeloma: assessment with melphalan and prednisone) trial, one

The initial Phase I clinical trial of LX1032 is planned as a double-blind, randomized, placebo-controlled, ascending single-dose study in healthy volunteers. This study is designed to evaluate the

The commission’s decision is applicable to the 27 member states of the European Union (EU), including France, Germany, Italy, Spain and the UK. Separate national licenses, based on

The supplemental new drug application (sNDA) application includes 48-week data from two phase III studies, ARTEMIS (antiretroviral therapy with TMC114 examined in naive subjects) and TITAN (TMC114/ritonavir in

The Phase I trial will evaluate the safety and efficacy of CB3304 (noscapine) administered daily to patients with relapsed or refractory multiple myeloma. The trial will be conducted

The new drug application (NDA) has been submitted for two indications, treatment of adults with worsening heart failure and treatment of hyponatremia. These indications are based on data